허가사항 범위 내에서 아래와 같은 기준으로 투여 시 요양급여를 인정하며, 동 인정기준 이외에는 약값 전액을 환자가 부담토록 함.
- 아 래 -
가. 조현병의 치료
나. 양극성장애 1형의 유지치료를 위한 단독요법: 약물복용에 대한 순응도가 낮아 재발로 인한 입원 경험이 있는 환자(낮병동 입원은 제외함)
■ 고시 개정 고시번호(시행일자)
고시 제2019-21호(2019.2.1.)
■ 고시 개정 사유
국내·외 허가사항, 교과서, 임상진료지침, 임상논문, 관련 급여기준 등을 참고하여 양극성 장애 1형 유지치료에 급여를 인정함.
■ 관련문헌 등
？Pharmacotherapy: A Pathophysiologic Approach, 10e, 2017
？Harrison's Principles of Internal Medicine, 19e. 2015.
？Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e, 2018.
？Companion to Psychiatric Studies, 8th e, 2010.
？Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder, Published: 14 Mar 2018.
？Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology, published 15 Mar 2016.
？Calabrese J R et al, Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study, J Clin Psychiatry, 2017, 78(3):324-31.
？Calabrese J R et al, Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder, J Affect Disord. 2018 Feb;227:649-656.
？Calabrese J R et al, Aripiprazole once？monthly as maintenance treatment for bipolar I disorder: a 52？week, multicenter, open？label study, Int J Bipolar Disord. 2018 Jun 10;6(1):14.
？Lahteenvuo M et al., Real-World Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder, JAMA Psychiatry. 2018 Apr 1;75(4):347-355.
？Lang K et al, Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics, J Med Econ. 2011;14(2):217-26.